Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention provides chimeric IBDV immunogens which actively protect against virulent and lethal challenge by Classic and variant IBDV strains, and methods for obtaining vaccines containing these chimeric immunogens and vaccines.
2. Discussion of the Background
Infectious bursal disease virus (IBDV) is responsible for a highly contagious immunosuppressive disease in young chickens which causes significant losses to the poultry industry worldwide (reviewed in Kibenge (1988) "J. Gen. Virol.", 69:1757-1775). Infection of susceptible chickens with virulent IBDV strains can lead to a highly contagious immunosuppressive condition known as infectious bursal disease (IBD). Damage caused to the lymphoid follicles of the bursa of Fabricius and spleen can exacerbate infections caused by other agents and reduce a chicken's ability to respond to vaccination as well (Cosgrove (1962) "Avian Dis.", 6:385-3894).
There are two serotypes of IBDV (McFerran et al (1980) "Avian Path.", 9:395-404). Serotype 1 viruses are pathogenic to chickens and differ markedly in their virulence (Winterfield et al (1978) "Avian Dis.", 5:253-260), whereas serotype 2 viruses, isolated from turkeys, are avirulent for chickens (Ismail et al (1988) "Avian Dis.", 32:757-759; Kibenge (1991) "Virology", 184:437-440).
IBDV is a member of the Birnaviridae family and its genome consists of two segments of double-stranded RNA (Dobos et al (1979) "J. Virol.", 32:593-605). The smaller segment B (.about.2800 bp) encodes VP1, the dsRNA polymerase. The larger genomic segment A (.about.3000 bp) encodes a 110 kDA precursor polyprotein in a single open reading frame (ORF) that is processed into mature VP2, VP3 and VP4 (Azad et al (1985) "Virology", 143:35-44). From a small ORF partly overlapping with the polyprotein ORF, segment A can also encode VP5, a 17 kDa protein of unknown function (Kibenge et al (1991) "J. Gen. Virol.", 71:569-577).
While VP2 and VP3 are the major structural proteins of the virion, VP2 is the major host-protective immunogen and causes induction of neutralizing antibodies (Becht et al (1988) "J. Gen. Virol.", 69:631-640; Fahey et al (1989) "J. Gen. Virol.", 70:1473-1481). VP3 is considered to be a group-specific antigen because it is recognized by monoclonal antibodies (Mabs) directed against VP3 from strains of both serotype 1 and 2 (Becht et al (1988) "J. Gen. Virol.", 69:631-640). VP4 is a virus-coded protease and is involved in the processing of the precursor protein (Jagadish et al (1988) "J. Virol.", 62:1084-1087).
In the past, control of IBDV infection in young chickens has been achieved by live vaccination with avirulent strains, or principally by the transfer of maternal antibody induced by the administration of live and killed IBDV vaccines to breeder hens. Unfortunately, in recent years, virulent variant strains of IBDV have been isolated from vaccinated flocks in the United States (Snyder et al (1988) "Avian Dis.", 32:535-539; Van der Marel et al (1990) "Dtsch. Tierarztl. Wschr.", 97:81-83). The use of a select panel of Mabs, raised against various strains of IBDV, has led to the identification of naturally occurring GLS, DS326, RS593 and Delaware variant viruses in the United States. Substantial economic losses have been sustained due to the emergence of these antigenic variants (Delaware and GLS) in the field (Snyder et al (1992) "Arch. Virol.", 127:89-101, U.S. application Ser. No. 08/216,841, filed Mar. 24, 1994, Attorney Docket No. 2747-053-27, Snyder, now abandoned). These variant strains are antigenically different from the Classic strains of IBDV most typically isolated before 1985, and lack epitope(s) defined by neutralizing monoclonal antibodies (Mabs) B69 and R63 (Snyder et al (1988) "Avian Dis.", 32:527-534; Snyder et al (1988) "Avian Dis.", 32:535-539; Snyder et al (1992) "Arch. Virol.", 127:89-101). Since the appearance of these variant strains in the field, many commercially available live and killed vaccines for IBDV have been reformulated in an attempt to better match the greater antigenic spectrum of viruses recognized to be circulating in the field.
Efforts to develop a recombinant vaccine for IBDV have been made, and the genome of IBDV has been cloned (Azad et al (1985) "Virology", 143:35-44). The VP2 gene of IBDV has been cloned and expressed in yeast (Macreadie et al (1990) "Vaccine", 8:549-552), as well as in recombinant fowlpox virus (Bayliss et al (1991) "Arch. Virol.", 120:193-205). When chickens were immunized with the VP2 antigen expressed from yeast, antisera afforded passive protection in chickens against IBDV infection. When used in active immunization studies, the fowlpox virus-vectored VP2 antigen afforded protection against mortality, but not against damage to the bursa of Fabricius.
Recently, the synthesis of VP2, VP3 and VP4 structural proteins of the variant GLS IBDV strain in a baculovirus expression system has been described (Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). In an initial two dose active immunity study in SPF chickens, baculovirus expressed GLS proteins were able to confer 79% protection against virulent GLS challenge (Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). In a subsequent extended study of active cross-immunity, by increasing the antigenic mass of the baculovirus expressed GLS protein, complete protection against the variant GLS and E/Del strains was obtained with a single dose, but only partial protection was afforded against the Classic STC strain unless two doses were administered.
In recent years, the complete, nucleotide sequences of the large segment A of five serotype 1 IBDV strains; 002-73 (Hudson et al (1986) "Nucleic Acids Res.", 14:001-5012), Cu-1, PBG98, 52/70 (Bayliss et al (1990) "J. Gen. Virol.", 71:1303-1312), STC (Kibenge (1990) "J. Gen. Virol.", 71:569-577), and serotype 2 OH strain (Kibenge (1991) "Virology", 184:437-440) have been determined. In addition, the VP2 gene of virulent Japanese IBDV strains (Lin et al (1993) "Avian Dis.", 37:315-323) and Delaware variants A and E (Lana et al (1992) "Virus Genes", 6:247-259; Heine et al (1991) "J. Gen. Virol.", 22:1835-1843) have been sequenced. However, noone has completely cloned and characterized the entire long segment of any United States IBDV variant.
SUMMARY OF THE INVENTION
The inventors have now identified the region of the IBDV genome which is responsible for antigenic variation. A DNA sequence containing the central variable region of VP2 protein, as well as a plasmid incorporating the same, have been constructed. This DNA sequence can be manipulated to generate desired virus neutralizing epitopes or immunogenic polypeptides of any IBDV strain. In turn, these immunogenic segments can be incorporated into new recombinant IBDV vaccines.

BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A and 1B illustrate the construction of various chimeric plasmids encoding IBDV-specific polyproteins. A map of the IBDV genome with its coding regions is shown at the top of the Figure. Selected restriction sites are incorporated in the Figure: B, BamHI; E, BstEII; N, NdeI; R, NarI; S, SpeI. Dashes indicate the substitution of the D78 sequence (NdeI-NarI fragment) into the GLS sequence to restore the B69 epitope region. Solid line and dotted line indicate the substitution of the E/Del-22 and DS326 sequences, respectively, into the GLS sequence to restore the B63 epitope region or to delete the 179 epitope region, respectively.
FIGS. 2A and 2B are electron micrographs of IBDV virus-like particles (=100 nm). A. Actual empty particles (without RNA) from purified virus. B. Virus-like particles (empty capsids) derived from a recombinant baculovirus expressing the large genome segment of IBDV in insect cells.
FIGS. 3A-3I show a comparison of the deduced amino acid sequences of the structural proteins (VP2, VP3 and VP4) of ten IBDV strains (SEQ ID NO:1-10). Dashes (-) indicate amino acid identity and crosses (x) denote a region where the sequence was not determined. Filled bar (.rect-ver-solid.) indicates a gap in the sequence and vertical arrowheads (.dwnarw.) mark the possible cleavage sites of VP2/VP4 and VP4/VP3. The two hydrophilic peaks in the variable region are overlined.
FIG. 4 is a phylogenetic tree for the IBDV structural proteins using the PAUP (phylogenetic analysis using parsimony) version 3.0 program (Illinois Natural History Survey, Champaign, Ill.).
FIGS. 5A-5K reflect the DNA (SEQ ID NO:11) and amino acid sequence (SEQ ID NO:12) for the GLS virus structural protein fragment VP2/VP4/VP3. A vertical line indicates the start/stop points for the VP2, VP4 and VP3 regions.
FIGS. 6A-6M reflect the DNA (SEQ ID NO:13) and amino acid sequence (SEQ ID NO:14) for the E/Del 22 virus structural protein fragment VP2/VP4/VP3.
FIGS. 7A and 7B show a table of the amino acid identities for key locations (epitopic determinants) of eight different IBDV.

DEFINITIONS
IBD--infectious bursal disease as described above.
IBDV--infectious bursal disease virus, a virus capable of, at a minimum, inducing lesions in the bursa of Fabricius in infected poultry.
Epitopic Determinants--amino acids or amino acid sequences which correspond to epitopes recognized by one or more monoclonal antibodies. Presence of the amino acid or amino acid sequence at the proper ORF location causes the polypeptide to exhibit the corresponding epitope. An epitopic determinant is identified by amino acid(s) identity and sequence location.
Genetic Epitopic Determinants--nucleotide sequences of the ORF which encode epitopic determinants.
Conformational Epitopes--epitopes induced, in part or in whole, by the quaternary (three-dimensional) structure of an IBDV polypeptide. Conformational epitopes may strengthen binding between an IBDV and a monoclonal antibody, or induce binding whereas the same sequence, lacking the conformational epitope, would not induce binding between the antibody and the IBDV polypeptide at all.
Virus-Like Particles--three-dimensional particles of natural or recombinant amino acid sequences mimicking the three-dimensional structure of IBDV (encoded by the large genome segment A) but lacking viral RNA. Virus-like particles exhibit conformational epitopes exhibited by native viruses of similar sequence. Virus-like particles are created by the proper expression of DNA encoding VP2, VP4, VP3 structural proteins in a proper ORF.
Epitopic Determinant Region--Limited region of amino acid sequence of VP2 of IBDV that is replete with epitopic determinants, variation among amino acids of this limited region giving rise to a high number of epitopes recognized by different monoclonal antibodies.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Recombinant, immunogenic polypeptides exhibiting the epitopes of two or more native IBDV, as well as recombinant virus-like particles exhibiting the epitopes of two or more native IBDV and conformational epitopes are effective immunogens for vaccines which can be used to confer protection against a wide variety of IBDV challenge in inoculated poultry. The recombinant polypeptides and virus-like particles are obtained by the expression of chimeric DNA prepared by the insertion, in the VP2 region of a base IBDV, of epitopic determinants for at least a second IBDV. This is most easily done by substitution of the genetic epitopic determinants for the amino acids identities and locations reflected in FIG. 7. Thus, where the epitopic determinant of the second IBDV differs from that of the base IBDV, the genetic epitopic determinant for the differing second IBDV id inserted in place of the genetic epitopic determinant at that location of the base IBDV. An example, combining epitopic determinants from the D78, E/Del 22 and DS326 IBDV into the base GLS IBDV is set forth in FIG. 1. Thus, one DNA sequence can be prepared with genetic epitopic determinants for a plurality of native IBDV. These recombinant plasmids can be inserted into a variety of packaging/expression vector, including baculovirus, fowlpox virus, Herpes virus of turkeys, adenovirus and similar transfection vectors. The vectors can be used to infect conventional expression cells, such as SF9 cells, chicken embryo fibroblast cell lines, chicken embryo kidney cells, vero cells and similar expression vehicles. Methods of transfection, and methods of expression, as well as plasmid insertion into transfection vehicles, are well known and do not constitute an aspect of the invention, per se.
The expression of the chimeric cDNA of the invention generate immunogenic polypeptides which reflect epitopes of a plurality of native IBDV, and the expression of a recombinant VP2, VP4, VP3 cDNA segment, with the VP2 region again comprising genetic epitopic determinants for at least two native IBDV give rise to immunogenic virus-like particles.
The immunogenic polypeptides and virus-like particles can be harvested using conventional techniques (Dobos et al, "J. Virol.", 32:593-605 (1979)). The polypeptides and virus-like particles can be used to prepare vaccines which will confer protection on inoculated poultry, in particular, chickens, and in a preferred embodiment, broiler chickens, protection against challenge from each IBDV bearing an epitope reflected in the plurality of epitopic determinants present in the inoculum. Thus, a single immunogen gives rise to immunity against a variety of IBDV, each IBDV whose genetic epitopic determinant has been incorporated in the chimeric cDNA.
The administration of the vaccines can be effectively done according to well-established procedures. In U.S. Pat. No. 5,064,646, which is incorporated herein by reference, methods are described for the effective inoculation of chicks based on the then novel isolation of GLS IBDV. Similar administration and dosage regimens can be employed herein. Since the polypeptides and virus-like particles lack viral RNA, they are avirulent. The vaccines may therefor be prepared by simple incorporation of the immunogenic polypeptides and virus-like particles in a pharmaceutical carrier, typically a suspension or mixture. Appropriate dosage values are best determined through routine trial and error techniques, given the different antibody titers induced and/or the quantity of different epitopes present which will induce complete cross-immunity to virulent challenge. In general, pharmacologically acceptable carriers such as a phosphate buffered saline, cell culture medium, Marek's virus vaccine diluent oil adjuvants and other adjuvants, etc., can be used. Administration is preferablly done to hens entering egg laying periods which provides induction of antibody which is passively transferred through the egg to the chick to prevent early invention by virulent field strength IBDV. Conversely, the recombinant vaccine may be delivered in a replicating vector at any time in a chicken's life span, preferably at one day of age. Experience has demonstrated that, generally, that the level of protection may be improved by a second inoculation.
This invention may be further understood by reference to the specific examples set forth below.
EXAMPLES
Background Methodology
To determine the molecular basis of antigenic variation in IBDV, the genomic segment A of four IBDV strains: GLS, DS326, Delaware variant E (E/Del) and D78 was cloned and characterized by sequencing. By comparing the deduced amino acid sequences of these strains with other serotype 1 and 2 sequences published previously, the putative amino acid residues involved in the binding with various neutralizing Mabs were identified, and the phylogenetic relationship of IBDV structural proteins was examined.
GLS, DS326 and STC strains of IBDV were propagated in the bursa of specific-pathogen-free chickens (SPAFAS, Inc., Norwich, Conn., USA). Tissue culture adapted E/Del-22, D78 and OH (serotype 2) strains of IBDV were propagated in primary chicken embryo fibroblast cells derived from 10-day-old embryonated eggs (SPAFAS, Inc.) and purified as described (Snyder et al (1988a) "Avian Dis.", 32:527-534). The Mabs against various strains of IBDV were produced and characterized using protocols previously outlined (Snyder et al (1988a) "Avian Dis.", 32:527-534; Snyder et al (1988) "Avian Dis.", 32:535-539). Mabs B69 and R63 were prepared against D78 strain, whereas Mabs 8, 10, 57 and 179 were prepared against GLS strain. In addition, a new Mab 67 was prepared which was neutralizing and specific for the E/Del strain. Identification of IBDV antigens by modified antigen capture ELISA (AC-ELISA) was carried out as described (Snyder et al (1992) "Arch. Virol.", 127:89-101).
Various strains of IBDV were characterized by their reactivities with a panel of neutralizing Mabs, as shown in Table 1.
TABLE 1______________________________________Antigenic characterization of various IBDV strains by their reactivitieswith a panel of neutralizing MAbs Classi- Reactivities with MAbsVirus Strains fication B69 R63 179 8 10 57 67______________________________________D78 Classic + + + + + - -PBG98 Classic - + + + + - -STC Classic + + + + + - -52/70 Classic + + + + - - -OH (serotype 2) Classic + + + + - - -E/Del Variant - + + + - - +GLS Variant - - + + + + -DS326 Variant - - - + + + -______________________________________
All standard serotype 1 viruses reacted with Mabs B69, R63, 179 and 8, except PBG98 (a British vaccine strain, Intervet, U. K.) which did not react with Mab B69. In contrast, all the U.S. variant viruses lack the virus-neutralizing B69 epitope. In addition, GLS and DS326 variants lack an R63 epitope but share a common epitope defined by the Mab 57. Thus, on the basis of the reactivities with various Mabs, these viruses were antigenically grouped as classic, GLS, DS326 and E/Del variants.
Complementary DNA clones, containing the entire coding region of the large RNA segment of various IBDV strains, were prepared using standard cloning procedures and methods previously described (Vakharia et al (1992) "Avian Dis.", 36:736-742; Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). The complete nucleotide sequence of these cDNA clones was determined by the dideoxy method using a Sequenase DNA sequencing kit (U.S. Biochem. Corp., Columbus, Ohio). DNA sequences and deduced amino acid sequences were analyzed by a PC/GENE software package (Intelligenetics, Inc.). these are reflected in FIGS. 5 and 6. The nucleotide sequence data of the GLS strain has been deposited with GenBank Data Libraries and has been assigned an accession number M97346.
Comparisons of the nucleotide sequence of GLS strain (3230 bp long) with eight serotype 1 and one serotype 2 IBDV strains exhibit .gtoreq.92% and .gtoreq.82% sequence homology, respectively; indicating that these viruses are closely related. It is interesting to find that there are only six to nine base substitutions between D78, PBG98, and Cu1 strains which corresponds to a difference of about 0.2% to 0.3% (results not shown). FIG. 3 and Table 2 show a comparison of the deduced amino acid sequences and percent homology of the large ORF of segment A of the ten IBDV strains, including four IBDV strains used in this study.
TABLE 2__________________________________________________________________________Percent amino acid sequence homology of large ORF of segment A of tenIBDV strainsStrain GLS DS326 E/Del D78 Cu-1 PBG98 52/70 STC 002-73 OH__________________________________________________________________________GLSDS326 98.7E/Del 98.4 98.3D78 98.5 98.1 97.9Cu-1 98.6 98.2 98.0 99.6PBG98 98.5 98.1 97.9 99.5 99.552/70 98.1 98.1 97.9 98.4 98.5 98.3STC 97.7 98.0 97.5 98.4 98.5 98.3 98.3002-73 97.0 97.1 96.7 97.6 97.7 97.6 97.3 97.4OH 90.0 90.0 89.7 90.2 90.3 90.2 89.8 90.3 90.1__________________________________________________________________________
These comparisons show that the proteins are highly conserved. The degree of difference in the amino acid sequence ranges from 0.4% for the D78 versus Cu-1 comparison and 10.3% for the serotype 1 (E/Del) versus serotype 2 (OH) comparison (Table 2).
In FIG. 3, alignments of the deduced amino acid sequences of the large ORF (1012 residues) of ten IBDV strains (including four used in this study) show that most of the amino acid changes occur in the central variable region between residues 213 and 332 of VP2 protein, as shown earlier by Bayliss et al (1990) "J. Gen. Virol.", 71:1303-1312. It is interesting to note that all the U.S. variants (GLS, DS326 and E/Del) differ from the other strains in the two hydrophilic regions which are overlined in FIG. 3 (residues 212 to 223 and residues 314 to 324). These two hydrophilic regions have been shown to be important in the binding of neutralizing Mabs and hence may be involved in the formation of a virus-neutralizing epitope (Heine et al (1991) "J. Gen. Virol.", 22:1835-1843). Recently, we demonstrated that the conformation dependent Mabs B69, R63, 8, 179, 10, and 57 (see Table 2) immunoprecipitate VP2 protein (Snyder et al (1992) "Arch. Virol.", 127:89-101). In addition, E/Del specific Mab 67 also binds to VP2 protein. Therefore, to identify the amino acids involved in the formation of virus-neutralizing epitopes, and hence the antigenic variation, we compared the amino acid sequences of VP2 protein of classic and variant viruses.
Comparison of the D78 sequence with the PBG98 sequence shows only four amino acid substitutions at positions 76, 249, 280 and 326. However, STC and 52/70 strains also differ from the D78 sequence at positions 76, 280 and 326 but these viruses do bind to Mab B69. This implies that Gln at position 249 (Gln249) may be involved in the binding with Mab B69. It should be noted that all U.S. variant viruses have a Gln.fwdarw.Lys substitution at this position and hence escape the binding with neutralizing Mab B69. Similarly, comparison of the GLS sequence with the DS326 sequence in the variable region shows six amino acid substitutions at positions 222, 253, 269, 274, 311 and 320. However, other strains of IBDV that do bind to Mab 179 have amino acid substitutions at positions 222, 253, 269 and 274 that are conservative in nature. Therefore, this suggests that Glu311 and Gln320 may be involved in the binding with Mab 179. Again, comparison of GLS and DS326 sequences with all other IBDV sequences shows a unique Ala.fwdarw.Glu substitution at position 321, suggesting the contribution of this residue in the binding with Mab 57. Since Mab 57 does not compete with Mab R63, it is conceivable that Ala321 may contribute to the binding with Mab R63. Similarly, comparison of E/Del sequence with other sequences shows five unique substitutions at positions 213, 286, 309, 318 and 323. However, comparison of this E/Del sequence (from tissue culture derived virus) with previously published VP2 A/Del and E/Del sequences (bursa derived virus) suggests the involvement of Ile286, Asp318 and Glu323 in the binding with Mab 67 since residues at positions 213 and 309 are not substituted in A/Del and E/Del sequences, respectively (Heine et al (1991) "J. Gen. Virol.", 22:1835-1843; Lana et al (1992) "Virus Genes", 6:247-259; Vakharia et al (1992) "Avian Dis.", 36:736-742).
Comparisons of the amino acid sequence also show a striking difference between serotype 1 and serotype 2 sequences. In serotype 2 OH strain, there is an insertion of an amino acid residue at position 249 (serine) and a deletion of a residue at position 680. Previously, it has been shown that serotype 2 viruses are naturally avirulent and do not cause any pathological lesions in chickens (Ismail et al (1988) "Avian Dis.", 32:757-759). Thus, these subtle changes in the structural proteins of serotype 2 OH strain may play an important role in the pathogenicity of the virus. Moreover, it has been hypothesized that an amino acid sequence motif, S-W-S-A-S-G-S, (residues 326 to 332; SEQ ID NO:15) is conserved only in virulent strains and could be involved in virulence (Heine et al (1991) "J. Gen. Virol.", 22:1835-1843). This sequence motif was also conserved in various pathogenic strains of IBDV isolated in Japan (Lin et al (1993) "Avian Dis.", 37:315-323). Comparison of the amino acid sequences in this heptapeptide region reveals that nonpathogenic serotype 2 OH strain has three substitutions, whereas mildly pathogenic strains of serotype 1 (D78, Cu-1, PBG98 and 002-73) have one or two substitutions in this region. Moreover, comparison of the hydrophilicity plots of the variable region (amino acids 213 to 332) of variant serotype 1 strains and serotype 2 OH strain indicates a drastic reduction in the second hydrophilic peak region (amino acid residues 314 to 324) for serotype 2 (results not shown). Since most of the amino acid residues causing antigenic variation reside in this region, these residues may play an important role in the formation of virus-neutralizing epitopes, as well as serotype specificity.
To evaluate the antigenic relatedness of structural proteins of various IBDV strains, a phylogenetic tree was constructed, based on the large ORF sequences of ten IBDV strains, including the U.S. variant strains examined in this study (FIG. 4). Three distinguishable lineages were formed. The first one, which is most distant from the others, is serotype 2 OH strain, and the second one is the geographically distant Australian serotype 1 strain (002-73). The third lineage consists of four distinct groups. The first and second group include highly pathogenic strains, namely, standard challenge (STC) strain from U.S. and the British field strain (52/70). The third group comprises all the European strains: the vaccine strains D78 (Holland), PBG98 (U.K.), and mildly pathogenic strain Cu-1 (Germany). The fourth group consists of the U.S. variant strains in which E/Del forms a different subgroup. The groups formed by the phylogenetic analysis correlate very well with the Mabs reactivity patterns (see Table 1). As shown in FIG. 4, all the U.S. variant viruses which lack the B69 epitope form a distinct group, whereas all the classic viruses containing a B69 epitope form another group (except PBG98). In addition, closely related GLS and DS326 strains containing a common Mab 57 epitope and lacking an R63 epitope could be separated from the other variant E/Del strain.
Based on this information, a recombinant vaccine was constructed as follows:
Construction of recombinant baculovirus clones containing chimeric IBDV genes
A recombinant baculovirus which expresses a chimeric VP2, VP3 and VP4 structural proteins of the GLS strain was constructed and assessed. The recombinant baculovirus expressed a chimeric VP2 protein incorporating all Mab defined GLS neutralization sites, as well as one neutralization site (B69) which is specific for Classic strains of IBDV in the form of a VP2-VP4-VP3 segment.
Complementary DNA clones, containing the entire coding region of the large RNA segment of the GLS and D78 IBDV strains, were prepared using standard cloning procedures and methods previously described (Vakharia et al (1992) "Avian Dis.", 36:736-742; Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). To insert the gene sequence encoding the B69 epitope of the D78 IBDV strain, plasmid pB69GLS was constructed as follows (see FIG. 1). Full-length cDNA clones of D78 and GLS (plasmids pD78 and pGLS-5) were digested with NdeI-NarI and NarI-SpeI enzymes to release a NdeI-NarI (0.26 kb) and a NarI-SpeI (0.28 kb) fragments, respectively. These two fragments were then ligated into the NdeI-SpeI cut plasmid pGLS-5 to obtain a chimeric plasmid pB69GLS. As a result of this insertion, three amino acids were substituted in the GLS VP2 protein. These substitutions were at positions 222 (Thr-Pro), 249 (Lys-Gln) and 254 (Ser-Gly) in the variable region of the VP2 protein (Vakharia et al (1992) "Avian Dis.", 36:736-742). To insert the chimeric IBDV structural genes in the Baculovirus genome, plasmid pB69GLS was completely digested with BstEII enzyme and partially with the BamHI enzyme, combined with the NheI-BstEII fragment (derived from plasmid pGLSBacI, see Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206) and then ligated to the NheI-BamHI cut transfer vector pBlueBacII (Invitrogen Corp., San Diego, Calif.). Finally, recombinant baculovirus I-7 was obtained using previously described procedures (Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). See Table 3.
Preparation of an inoculum for immunization
Spodoptera frugiperda SF9 cells, infected at a mutiplicity of 5 PFU per cell with the I-7 recombinant baculovirus, were propagated as suspension cultures in one liter flasks containing Hink's TNM-FH medium (JHR Biosciences, Lenxa, Kans.) supplemented with 10% fetal calf serum at 28.degree. C. for 3 to 4 days. The infected cells were recovered by low speed centrifugation, washed two times with PBS, and resuspended in a minimum volume of PBS. The cell slurry was sonicated on and ice bath three times for 1 min, with 2 min intervals and clarified by low speed centrifugation. An aliquot of each cell lysate was tested with anti-IBDV Mabs by AC-ELISA to estimate the antigenic mass present (Snyder et al (1988) "Avian Dis.", 32:535-539). Preparations having the highest antigenic mass were pooled and comparatively titrated in AC-ELISA against the V-IBDV-7-1 recombinant baculovirus IBDV vaccine used in a previous study (Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). The antigenic mass of the I-7 recombinant preparation, as determined by AC-ELISA with group specific neutralizing Mab 8, was adjusted by dilution to be the same as the V-IBDV-7-1 vaccine, and then it was emulsified with an equal volume of Freund's incomplete adjuvant and used for inoculation.
Viruses
The challenge viruses: Classic strains IM and STC, and variant strains E/Del and GLS-5 were obtained from previously acknowledged sources (Snyder et al (1988) "Avian Dis.", 32:527-534; Snyder et al (1992) "Arch. Virol.", 127:89-101). After intraocular instillation, challenge viruses were titrated in the bursae of specific-pathogen-free (SPF) chickens (SPAFAS, Inc., Storrs, Conn.). For strains STC, E/Del and GLS-5, a 100 chick infective fifty percent dose (100 CID.sub.50) was determined based on bursa to body weight measurements. One hundred lethal doses (100 LD) of the IM strain were calculated based on mortality at 8 days post-inoculation (PI).
Chicken inoculations and IBDV challenge
White leghorn SPF chickens were hatched and reared in HEPA filtered isolation units (Monair Anderson, Peachtree City, Ga.). Eight-week old chickens were prebled, individually wing banded, divided among 10 groups of 15 chicks each and treated as follows. Chickens of groups I-V received no inoculations and served as either negative or positive challenge controls. Chickens of group V-X were inoculated intramascularly with 0.5 ml of the 1-7 inoculum prepared above from recombinant Baculovirus infected cell lysates. At 3 weeks PI, all chickens were bled and chickens of groups II-IX were challenged with the appropriate IBDV challenge strain by ocular instillation. Four days post-challenge, 5 chickens from each group were humanely sacrificed and their cloacal bursa were removed. Each bursa was processed and subsequently evaluated for the presence of IBDV antigen by AC-ELISA (Antigen Capture Enzyme Linked Immunosorbent Assay) as described (Snyder et al) (1988) "Avian Dis.", 32:535-539). In addition, chickens in the IM challenged groups were scored as dead, and humanely sacrificed when they became obviously moribund due to IM challenge. Eight days post-infection, the remaining chickens in all groups were sacrificed and weighed. The bursa of Fabricius from each chicken was carefully excised and also weighed. Bursa weight to body weight ratio was calculated for each chicken as described by Lucio and Hitchner (Lucio et al (1979) "Avian Dis.", 23:466-478). Any value for individually challenged chickens falling plus or minus two standard deviation units from the mean of the corresponding control groups was scored as a positive indicator of IBDV infection. Opened bursa were fixed by immersion in 10% neutral buffered formalin. Transverse portions of bursae were processed through graded alcohols and xylene, embedded into paraffin, sectioned, stained with hematoxylin-eosin, and examined with a light microscope. Protection against challenge was defined as the absence of any IBDV-induced lesions in the bursa of Fabricius.
Serological evaluation
The Classic D78 strain, as well as the cell culture adapted variant GLS strain of IBDV were grown in primary chicken embryo fibroblast cells and used in virus neutralization (VN) tests to test sera from the vaccine trial essentially as described (Snyder et al (1988) "Avian Dis.", 32:527-534). Serum from the trials was also tested for the presence of anti-IBDV antibody using a commercially available IBDV antibody ELISA kit (Kirkegaard and Perry, Gaithersburg, Md.).
Evaluation of vaccines and challenge viruses
The antigenic content of the I-7 GLS chimeric IBDV vaccine was assessed in AC-ELISA with a panel of VP2 and VP3 specific Mabs. The relative antigenic mass of each epitope expressed in the I-7 vaccine was compared to previously tested lots of Baculovirus expressed unmodified GLS subunit vaccines (Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). The status of each Mab defined epitope on the I-7 chimeric vaccine was also compared to the status of those Mab defined epitopes occurring on wild type IBDV challenge viruses used to evaluate the efficacy of the I-7 vaccine. Table 3 shows that the antigenic mass levels at the 8, 57, and B29 epitopes for the current I-7 chimeric vaccine were similar to a recently tested unmodified V-IBDV-7-1 GLS subunit vaccine, but approximately 4-fold higher than the original unmodified V-IBDV-7 vaccine.
TABLE 3__________________________________________________________________________Comparative levels of IBDV, VP2, and VP3 monoclonal antibody (Mab)defined epitopes onrecombinant baculovirus expressing IBDV proteins and status of Mabdefined epitopes onchallenge viruses used.Relative level of Mab epitope.sup.A Challenge Status of Mab epitope.sup.BVaccine 8 57 B69 67 B29 Virus 8.sup.C 57.sup.C B69.sup.C 67.sup.C B29.sup.D__________________________________________________________________________V-IBD-7.sup.E 1 1 0 0 1 GLS + + - - +V-IBD-7-1.sup.E 3 3 0 0 2 STC + - + - +I-7.sup.F 3 3 9 0 2 IM + - + - + E/Del + - - + +__________________________________________________________________________ .sup.A The relative level of each Mab epitope was determined by ACELISA, and the level of each Mab epitope was set to 1 for the VIBD-7 vaccine previously used (15). Maximum level is 9. Each 1.0 increment represents approximately twice the amount of the epitope present in the original VIBD-7 vaccine. The VIBD-7-1 vaccine was also previously reported (16). .sup.B The status of Mab epitopes was determined by ACELISA and is presented as present (+) or absent (-). .sup.C Neutralizing Mab epitope resides on VF2 or IBDV. .sup.D Nonneutralizing Mab epitope resides on VP3 of IBDV. .sup.E Recombinant baculovirus vaccines incorporating unmodified large segment A GLS proteins. .sup.F Current recombinant baculovirus vaccine incorporating modified chimeric large segment A GLS proteins.
A major difference in the unmodified and chimeric vaccines was the appearance of the Classic B69 epitope in the chimeric GLS product. The level of the B69 epitope was arbitrarily set at 9 since no comparisons could be made to the unmodified GLS subunit vaccines. By comparing the status of Mab defined epitopes on the challenge viruses with the unmodified and chimeric GLS subunit vaccines (Table 3), it could be seen that while the chimeric product had expressed the B69 epitope found on the Classic STC and IM challenge viruses, that it also retained all of the homologous GLS epitopes.
Active-cross protection
Table 4 shows the results of a cross-protection trial and serological results obtained prior to challenge.
TABLE 4__________________________________________________________________________Active cross-protection induced 2-weeks pest Immunization withbaculovirus expressed chimeric I-7IBDVantigens and associate prechallenge serology.Group Number Protected Mean VN Titer .sup.1 Leg MeanNo. Vaccination.sup.A Challenge.sup.B AC-ELISA.sup.C IIiste.sup.D DBWR.sup.D D78 GLS ELISA__________________________________________________________________________I None None NA NA NA .ltoreq.4 .ltoreq.4 0II None STC 0/5 0/10 0/10 .ltoreq.4 .ltoreq.4 0III None IM 0/5 .sup. 0/5.sup.E .sup. 5/5.sup.E .ltoreq.4 .ltoreq.4 0IV None E/Del 0/5 0/10 0/10 .ltoreq.4 .ltoreq.4 0V None GLS-5 0/5 0/10 0/10 .ltoreq.4 .ltoreq.4 0VI I-7 STC 5/5 10/10 10/10 .sup. 10.7 (1.8).sup.F .sup. 10.4 (1.4).sup.F .sup. 1235 (312).sup.FVII I-7 IM 5/5 10/10 10/10 10.0 (1.4) 10.4 (2.1) 1201 (791)VIII I-7 E/Del 5/5 10/10 10/10 11.4 (1.2) 10.6 (1.9) 1089 (409)IX I-7 GLS-5 5/5 10/10 10/10 11.0 (1.5) 12.0 (2.0) 1220 (339)X I-7 None 5/5 N/A N/A 9.9 (1.4) 9.3 (1.4) 1140 (473)__________________________________________________________________________ .sup.A Vaccination was given at 8weeks of age. .sup.B Challenge virus was given by intraocular instillation 3weeks post immunization or at 11weeks of age for controls. .sup.C Protection was determined by ACELISA examination of 1/2 of each group 4days postchallenge. .sup.D Protection was determined histologically and by bursa to body weight ratios at 8days. .sup.E Five chickens were scored as dead due to IM challenge propr to 8days postchallenge. .sup.F One standard deviation.
Groups II-V served as challenge controls and as indicated by AC-ELISA, bursa to body weight and histological assessments, all non-vaccinated chickens were fully susceptible to virulent IBDV challenged with all strains used. The IM challenge produced lethal disease in one-third of the control group chicks. In contrast, 8-week old chickens comprising Groups VI-IX were vaccinated once with the GLS chimeric vaccine, and 3-weeks PI all vaccinated chickens were completely protected from challenge by all challenge viruses, including lethal disease produced in controls by the IM strain. Serologically, titers form reciprocal-cross VN tests conducted on prechallenge sera with the D78 and GLS tissue culture viruses were essentially within 2-fold of one another. Mean ELISA titers were relatively low, but were also uniform between the vaccinated groups.
Characterization of vaccines
In initial studies with Baculovirus expressed subunit GLS vaccines, after administration of two doses, the V-IBDV-7 GLS vaccine (Table 3) could only induce active antibody levels capable of providing 79% protection against homologous GLS challenge (Vakharia et al (1993) "J. Gen. Virol.", 74:1201-1206). In a subsequent study, the antigenic mass of the original V-IBDV-7 vaccine was increased approximately 4-fold (calculated at the group specific Mab 8 site) and initiated one dose and two dose vaccination cross-challenge trials with the unmodified GLS subunit vaccine designated as V-IBDV-7-1 (Table 3). In those trials, two doses of the vaccine yielded complete cross-protection against virulent STC, E/DEL and GLS challenge. However, in the one vaccine dose trial, while complete protection was attained against challenge with variant E/DEL and GLS viruses, only 44% protection was achieved against the more distantly related Classic STC virus. Those studies could mean that simply by increasing the antigenic mass and/or doses of the vaccine that better cross-protection could be obtained. However, it was also evident in the absence of homologous vaccination that lower levels of antibody, induced by one dose of the GLS V-IBDV-7-1 subunit vaccine, were not sufficiently cross-protective against Classic IBDV challenge. This could means that in even lower levels of antibody, such as in cases of waning material antibody, that cross-protection would likely be even more reduced. Indeed, although not challenged with the STC virus, in some passive maternal antibody studies conducted using another dosage of the V-IBDV-7 vaccine, while homologous GLS protection was afforded, progeny of vaccinated hens were only 57% protected against a more closely related E/DEL challenge.
In a single-dose vaccination cross-challenge trial, the chimeric GLS I-7 vaccine, which incorporated the Classic B69 neutralization epitope, was evaluated. In order to make the current trial comparable to previous trials, the I-7 vaccine was formulated such that by AC-ELISA the relative antigenic mass of the I-7 chimeric subunit vaccine was nearly identical to the unmodified V-IBDV-7-1 vaccine previously used (Table 3). Table 4 shows the results of the cross-challenge after a single dose of the I-7 vaccine was administered. Results were similar to those obtained with the unmodified V-IBDV-7-1 vaccine previously used in that protection against the GLS and E/DEL strains was complete. However, the I-7 vaccine yielded complete protection against pathogenic and lethal challenge by the Classic STC and IM strains respectively. Since the antigenic mass of the GLS and group common epitopes on V-IBDV-7 and I-7 vaccines were carefully equilibrated and equal, it is reasonable to conclude that the comparative increase in efficacy of the I-7 vaccine against challenge with Classic IBDV strains was due solely to the incorporation of the Classic IBDV B69 neutralization epitope in the GLS VP2 protein sequence.
VIRUS-LIKE PARTICLES
As noted above, the recombinant cDNA and immunogens expressed thereby, of this invention may be confined to the VP2 immunogenic region. In other words, it may be sufficient to prepare a cDNA clone encoding epitopic determinants for a base IBDV, e.g., GLS, as well as a second IBDV epitopic determinant, such as D78. Other epitopic determinants, all in the VP2 epitopic determinant region may be incorporated, cloned and expressed as discussed above.
As reflected in FIG. 2, virus-like particles are generated by the expression of DNA encoding the VP2-VP4-VP3 structural protein sequences. These virus-like particle immunogens can be separated from the corresponding VP2 only immunogens, both in terms of monoclonal antibody and by conventional separation measures, such as electrophoresis and chromatography. The difference in reactivity with monoclonal antibody strongly indicates, however, that epitopes present in the VP2-VP4-VP3 structural protein sequence-induced virus-like particles are present that are not present in immunogens expressed by the identical VP2 only region. These epitopes are "both linear and conformational" epitopes. Conformational epitopes differ from linear epitopes and are reflected in the conformation, not only in amino acid sequence of the actual virus. As a result, inoculation of poultry with a recombinant virus-like particle may provide even superior protection against field challenge from IBDV than inoculation with the immunogens of the VP2 region only. This is due to the spontaneous assembly of all the structural elements of the virus.
Applicants have discovered that the expression of the VP2 region as part of the VP2-VP4-VP3 structural protein single segment generates virus-like particles such as those of FIG. 2. These particles have been demonstrated to react with antibodies which do not react similarly with the identical recombinant VP2 immunogen. Thus, the virus-like particles may give rise to higher antibody titers, and/or subtly different (broader) protection when a poultry host is inoculated therewith.
The invention herein therefore embraces (1) recombinant VP2 immunogens comprising epitopic determinants of at least two different IBDV strains and (2) virus-like particles of VP2-VP4-VP3 segments wherein the VP2 region again comprises epitopic determinants of at least two different IBDV strain, as well as the nucleotide sequences encoding both 1 and 2, and vaccines embracing the same.
RECOMBINANT EPITOPIC DETERMINANT COMBINATIONS
As reflected in the examples set forth above, genetic epitopic determinants for an IBDV strain can be inserted in the VP2 region of a different, base IBDV genetic sequence, and subsequently used to express an immunogen exhibiting epitopes for both IBDV. Indeed, the examples above demonstrate the combination of at least three different IBDV epitopic determinants. More can be combined. The resulting vaccine includes an active agent, the expressed immunogen, which provides challenge protection against a broad spectrum of IBDV, rather than prior art virus-based vaccines which give protection against a single strain, or a single family of strains.
FIG. 7 reflects the amino acid identities for the epitopic determinant region for seven different IBDV. These are not intended to be limiting, but are representative. Desirable recombinant immunogens, both VP2 only and virus-like particle VP2-VP4-VP3 immunogens are made by substituting the genetic epitopic determinants for the varying amino acids at the identified locations in FIG. 7 (locations not identified are conserved throughout the IBDV strains). This induces the expression of the inventive immunogens. Clearly, the possible combinations, while large in number, are limited, and may be investigated with routine skill. Representative combinations will tend to reflect combinations of epitopic determinants for dominant IBDV.
A E/Del/GLS recombinant may include changes in the E/Del epitopic determinant region at position 213, Asn-Asp, 253 Gln-His and 169 Thr Ser.
A DS326/D78 recombinant may include the amino acid, and corresponding nucleotide substitutions at 76Ser-Gly, 249 Lys-Gln, 253 Gln-His and 270 Ala-Thr substitutions.
Obviously, a wide variety of combinations are possible and will occur to those of skill in the art. The epitopic determinant region, roughly including the region from amino acid 5-433 of the VP2 region, thus constitutes a recombinant "cassette" which may be tailored by site-specific mutagenesis to achieve amino acid insertion and/or deletion to provide desired recombinant cDNA clones, polypeptides, virus-like particles and vaccines with improved protection against a wide variety of IBDV.
LETHAL IBDV, MONOCLONAL ANTIBODY AND VACCINE THEREFORE
As noted, typically, IBDV infection creates an immunosuppressive condition, and is reflected in lesions in the bursa of Fabricius. This is typical of IBDV countered in the United States. There exist, however, lethal IBDV, that is, IBDV infections which results in chicken mortality directly as a result of IBDV infection. While vaccines have been developed on the basis of isolation of these IBDV, the resulting vaccines are "hot", that is, they themselves create or induce an immunosuppressive condition, and the inoculated chick must be bolstered with antibodies to other infectious agents. This method of protection is so undesirable as to have been discontinued in most commercial poultry houses in Europe. No adequate safe vaccine against the lethal IBDV is currently available.
The inventors have developed a monoclonal antibody, Mab 21, deposited under Budapest Treaty conditions at the American Type Culture Collection, Deposit Accession No. ATCC HB 11566. This monoclonal antibody is specific and neutralizing for lethal IBDV strains. The specificity is reflected in Table 5, which confirms that unlike other monoclonal antibody, Mab 21 is specific for an epitope exhibited only by IBDV strains having lethal potential.
TABLE 5__________________________________________________________________________Source IBDV Strain Comment B29 8 B79 1* 63 69 21 67 57 5*__________________________________________________________________________ Lethal Potential IM+ + + + + + + + - - -Sharma IM + + + + + + + - - -USDA STC + + + + + + + - - -Spafas 2512 (Winterfield) + + + + + + + - - -Edgar Edgar (vaccine hot) + + + + + + + - - - Pathogenic VirusSterwin Bursa Vac (vaccine hot) + + + + + + + - - - Vaccine VirusASL Univax-BD (ST 14) + + + + + + - - - -Select Bursal Disease Vaccine (Luk) + + + + + + - - - -Select (STD + VAR) + + + + + + - - - - + + + + + + - - - -Key Vet Bio-Burs I (D78) + + + + + + - - - -Key Vet Bio-Burs W (Luk) + + + + + + - - - -Key Vet Key-Burs (D78) + + + + + + - - - -MBL Maryland (Master seed) + + + + + + - - - -Sterwin BVM (Baxendale) + + + + + +/- - - - -Sterwin 1048-B + + + + + +/- - - - -Lukert BVM (Lab Strain) + + + + + +/- - - - -CEVA Bursa Blend (2512) + + + + + + - - - -InterVet D78 + + + + + + - - - -InterVet Prime Vac + + + + + + - + + -InterVet 8903 + + + - + - - + - -Sofway Bursine (Luk) + + + + + + - - - -Sofway Bursine II (Luk+) + + + + + + - - - - Lab VirusJKR E/Del + + + - + - - + - -JKR A/Del + + + - + - - + - -KKR D/Del + + + - + - - + - -DBS GLS + + + + - - - - + -DBS DS326 + + - + - - - - + +*Skeele S977 + + + + + + - - - -OH (Serotype II) + + + + + + - - - -__________________________________________________________________________ *Field Strains: All classic field strains tested to date which were isolated in the U.S. have the 21 marker1 NOTE: 1. Lukert and STC are Edgar derivatives. 2. Univax is a Bursa Vac derivative. 3. Burse Blend is a 2512 Winterfield derivative.
It should be noted that throughout this application, reference is made to a variety of monoclonal antibody which are used to confirm the presence of epitopes of different IBDV in the inventive recombinant chimeric immunogens of the application. These monoclonal antibody have been also deposited under Budapest Treaty conditions and are freely available. They are not, however, necessary for the practice of this invention, and do not constitute an aspect thereof. This should be contrasted with Mab 21.
Like other Mab developed by the inventors herein for IBDV, passive immunization against IBDV lethal strains, particularly designed to achieve immunization in a uniform, standardized level, and to augment any maternally derived levels against lethal IBDV field infection can be obtained by vaccinating one-day old chicks with a vaccine comprising a pharmacologically acceptable carrier such as those described above, in which is present an amount of Mab 21 effective to provide enhanced protection for the inoculated chicks.
The necessary level of protection can be conferred to by a single dose of the vaccine administered in ova or to a day-old chick having a Mab 21 concentration of between 1 microgram and 1 milligram, or repeated vaccinations having a smaller effective dose, but carried out over time. If repeated vaccinations are used, the dosage levels should range between 1 microgram and 1 milligram. The concentration level needed to vaccinate older chickens increases with the weight of the bird and can be determined empirically.
Further investigation of the amino acid sequences of the lethal strains in the epitopic determinant region reflects the highly conserved 279 identity Asn at position 279 of VP2, in non-lethal strains, with a conserved Asp identity at the same position in lethal strains. Accordingly, the lethal strain epitopic determinant recognized by Mab 21, unique to the lethal strains, empirically differs from non-lethal IBDV by the substitution 279 Asp-Asn. According to the methods set forth above, a chimeric, recombinant immunogen conferring effective protection against lethal IBDV, something not possible previously with any type of vaccine without inducing an immunosuppressive condition, may be prepared by inserting the genetic epitopic determinant for 279 Asp in a non-lethal base IBDV, such as GLS. This will confer protection against the base IBDV, the lethal IBDV, as well as all other IBDV whose genetic epitopic determinants are inserted. Vaccines prepared from these immunogens, whether VP2 only, or in the form of virus-like particles of VP2-VP-VP3 segments, are used in the same fashion as discussed above.
__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 15- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: GLS- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Thr Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Lys Thr Se - #r Val His Ser Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Ser Ala Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Thr Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Glu Gly Asp Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Ser Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Ile Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Ile Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Ser Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ar - #g Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: DS326- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Ser Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Lys Thr Se - #r Val Gln Ser Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Ala Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Ala Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Lys Ile Val Thr Se - #r Lys Ser Gly Gly Leu305 3 - #10 3 - #15 3 -#20- Glu Gly Asp Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Ile Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Ala Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Tyr Gly Glu Il - #e Glu Lys Ile Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Ala Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ly - #s Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: E/DEL- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Gly Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Pro Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Gln Thr Se - #r Val His Gly Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Thr Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Thr Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Asp Gln Met Ser Trp Ser Ala Arg Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Val Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Val Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Arg Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Leu Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: D78- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:- Met Thr Asn Leu Gln Asp Gln Thr His Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Ser Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asn Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Thr Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Lys Thr Se - #r Val Gln Ser Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Ala Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Ala Gly Ile Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Ile Leu Glu Ile Val Thr Se - #r Lys Ser Asp Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Glu Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp His Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Ile Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Ile Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Gly945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: CU-1- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Pro Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Gln Thr Se - #r Val His Gly Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Thr Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Thr Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Ser Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Asp Gln Met Ser Trp Ser Ala Lys Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Val Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Val Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Leu Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: PBG98- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xa - #a Xaa Xaa Xaa Xaa Xaa# 15- Xaa Xaa Xaa Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Pro Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Arg Thr Se - #r Val His Gly Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Thr Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Thr Gly Leu Th - #r Thr Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Asp Gln Met Leu Trp Ser Ala Arg Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Val Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Val Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Leu Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: 52/70- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Pro Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Ile Gly Gly Glu Leu Val Phe Gln Thr Se - #r Val Gln Gly Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Ala Val Ile# 270- Thr Arg Ala Val Ala Ala Asp Asn Gly Leu Th - #r Ala Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Asp Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Val Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Pro Asn Ala Cys Gly Glu Il - #e Glu Lys Ile Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Asp Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Ser Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Thr Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Lys Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Asp Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: STC- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Leu#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Pro Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Gln Thr Se - #r Val Gln Gly Leu Val# 255- Leu Gly Ala Thr Ile Tyr Phe Ile Gly Phe As - #p Gly Thr Thr Val Ile# 270- Thr Arg Ala Val Ala Ala Asp Asn Gly Leu Th - #r Ala Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Val Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Asp Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Val Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Ile Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Phe Gly Glu Il - #e Glu Lys Val Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Ala Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Ala Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ly - #s Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Leu Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: 002-73- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:- Met Thr Asn Leu Ser Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Met Leu Gl - #n Ser Asn Gly Asn Tyr#80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Pro Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Asn Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Gln Thr Se - #r Val Gln Gly Leu Val# 255- Leu Asn Ala Thr Ile Tyr Leu Val Gly Phe As - #p Gly Thr Thr Val Thr# 270- Thr Arg Ala Val Ala Ala Gly Asn Gly Leu Th - #r Ala Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr Se - #r Glu Ile Thr Gln Pro# 300- Val Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Asp Gln Met Ser Trp Leu Ala Ser Gl - #y Asn Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Val Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Va - #l Glu Lys Val Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Ile Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Ser Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asp Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Ala# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Ser# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: protein- (vi) ORIGINAL SOURCE:#bursal disease virusM: Infectious (B) STRAIN: OH- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:- Met Thr Asn Leu Met Asp His Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Val Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Ser Tyr#80- Gln Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Val Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Ty - #r Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Ser# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Al - #a Gly Leu Asp Pro Lys# 190- Leu Met Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Val# 205- Thr Ala Ala Asp Glu Tyr Gln Phe Ser Ser Gl - #n Leu Ile Pro Ser Gly# 220- Val Lys Thr Thr Leu Phe Thr Ala Asn Ile As - #p Ala Leu Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Ile Phe Ser Gln Va - #l Thr Ile His Ser Ile# 255- Glu Val Asp Val Thr Ile Tyr Phe Ile Gly Ph - #e Asp Gly Thr Glu Val# 270- Thr Val Lys Ala Val Ala Thr Asp Phe Gly Le - #u Thr Thr Gly Thr Asn# 285- Asn Leu Val Pro Phe Asn Leu Gly Gly Pro Th - #r Ser Glu Ile Thr Gln# 300- Pro Ile Thr Ser Met Lys Leu Glu Val Val Th - #r Tyr Lys Arg Gly Gly305 3 - #10 3 - #15 3 -#20- Thr Ala Gly Asp Pro Ile Ser Trp Thr Val Se - #r Gly Thr Leu Ala Val# 335- Thr Ile Val Gly Gly Asn Tyr Pro Gly Ala Le - #u Arg Pro Val Thr Leu# 350- Val Ala Tyr Glu Arg Val Ala Ala Gly Ser Va - #l Val Thr Val Ala Gly# 365- Val Ser Asn Phe Glu Leu Ile Pro Asn Pro Gl - #u Leu Ala Lys Asn Leu# 380- Val Thr Glu Tyr Gly Arg Phe Asp Pro Gly Al - #a Met Asn Tyr Thr Lys385 3 - #90 3 - #95 4 -#00- Leu Ile Leu Ser Glu Arg Asp Arg Leu Gly Il - #e Lys Thr Val Trp Pro# 415- Thr Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Ph - #e Met Glu Val Ala Asp# 430- Leu Asn Ser Pro Leu Lys Ile Ala Gly Ala Ph - #e Gly Phe Lys Asp Ile# 445- Ile Arg Ala Ile Arg Lys Ile Ala Val Pro Va - #l Val Ser Thr Leu Phe# 460- Pro Pro Ala Ala Pro Leu Ala His Ala Asn Ar - #g Glu Gly Val Asp Tyr465 4 - #70 4 - #75 4 -#80- Leu Leu Gly Asp Glu Ala Gln Ala Ala Ser Gl - #y Thr Ala Arg Gly Ala# 495- Ser Gly Lys Ala Arg Ala Ala Ser Gly Arg Il - #e Arg Gln Leu Thr Leu# 510- Ala Ala Asp Lys Gly Tyr Glu Val Val Ala As - #n Met Phe Gln Val Pro# 525- Gln Asn Pro Ile Val Asp Gly Ile Leu Ala Se - #r Pro Gly Ile Leu Arg# 540- Gly Ala His Asn Leu Asp Cys Val Ser Lys Gl - #u Gly Ala Thr Leu Phe545 5 - #50 5 - #55 5 -#60- Pro Val Val Ile Thr Thr Leu Glu Asp Glu Le - #u Thr Pro Lys Ala Leu# 575- Asn Ser Lys Met Phe Ala Val Ile Glu Gly Al - #a Arg Glu Asp Leu Gln# 590- Pro Pro Ser Gln Arg Gly Ser Phe Ile Arg Th - #r Leu Ser Gly His Arg# 605- Val Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pr - #o Leu Glu Thr Gly Arg# 620- Asp Tyr Thr Val Val Pro Ile Asp Asp Val Tr - #p Asp Asp Ser Ile Met625 6 - #30 6 - #35 6 -#40- Leu Ser Gln Asp Pro Ile Pro Pro Ile Val Gl - #y Asn Ser Gly Asn Leu# 655- Ala Ile Ala Tyr Met Asp Val Phe Arg Pro Ly - #s Val Pro Ile His Val# 670- Ala Met Thr Gly Ala Leu Asn Ala Ser Glu Il - #e Glu Ser Val Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Met Lys Leu Ala# 700- Gly Pro Gly Asp Tyr Asp Ile Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Gly Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Thr Ala Gl - #y Arg Gln Phe His Leu# 750- Ala Leu Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Asp Ala# 765- Val Arg Ala Met Asp Ala Ala Ala Asn Ala As - #p Pro Leu Phe Arg Ser# 780- Ala Leu Gln Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Lys Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Ala Lys Asp Ala Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Glu Pro Asn Glu Asp Tyr Pro Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Arg Val Tyr Glu Thr Asn His Gly Ar - #g Val Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Ser# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3230 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 114..3149- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:- CCCCGGGGGA GTCACCCGGG GACAGGCCGT CAAGGCCTTG TTCCAGGATG GA - #ACTCCCCC 60- TTCTACAATG CTATCATTGA TGGTTAGTAG AGATCGGACA AACGATCGCA GC - #G ATG 116# Met# 1- ACA AAC CTG CAA GAT CAA ACC CAA CAG ATT GT - #T CCG TTC ATA CGG AGC 164Thr Asn Leu Gln Asp Gln Thr Gln Gln Ile Va - #l Pro Phe Ile Arg Ser# 15- CTT CTG ATG CCA ACA ACC GGA CCG GCG TCC AT - #T CCG GAC GAC ACC CTG 212Leu Leu Met Pro Thr Thr Gly Pro Ala Ser Il - #e Pro Asp Asp Thr Leu# 30- GAG AAG CAC ACT CTC AGG TCA GAG ACC TCG AC - #C TAC AAT TTG ACT GTG 260Glu Lys His Thr Leu Arg Ser Glu Thr Ser Th - #r Tyr Asn Leu Thr Val# 45- GGG GAC ACA GGG TCA GGG CTA ATT GTC TTT TT - #C CCT GGA TTC CCT GGC 308Gly Asp Thr Gly Ser Gly Leu Ile Val Phe Ph - #e Pro Gly Phe Pro Gly# 65- TCA ATT GTG GGT GCT CAC TAC ACA CTG CAG AG - #C AAT GGG AAC TAC AAG 356Ser Ile Val Gly Ala His Tyr Thr Leu Gln Se - #r Asn Gly Asn Tyr Lys# 80- TTC GAT CAG ATG CTC CTG ACT GCC CAG AAC CT - #A CCG GCC AGC TAC AAC 404Phe Asp Gln Met Leu Leu Thr Ala Gln Asn Le - #u Pro Ala Ser Tyr Asn# 95- TAC TGC AGG CTA GTG AGT CGG AGT CTC ACA GT - #A AGG TCA AGC ACA CTC 452Tyr Cys Arg Leu Val Ser Arg Ser Leu Thr Va - #l Arg Ser Ser Thr Leu# 110- CCT GGT GGC GTT TAT GCA CTA AAC GGC ACC AT - #A AAC GCC GTG ACC TTC 500Pro Gly Gly Val Tyr Ala Leu Asn Gly Thr Il - #e Asn Ala Val Thr Phe# 125- CAA GGA AGC CTG AGT GAA CTG ACA GAT GTT AG - #C TAC AAT GGG TTG ATG 548Gln Gly Ser Leu Ser Glu Leu Thr Asp Val Se - #r Tyr Asn Gly Leu Met130 1 - #35 1 - #40 1 -#45- TCT GCA ACA GCC AAC ATC AAC GAC AAA ATT GG - #G AAC GTC CTA GTA GGG 596Ser Ala Thr Ala Asn Ile Asn Asp Lys Ile Gl - #y Asn Val Leu Val Gly# 160- GAA GGG GTT ACT GTC CTC AGC TTA CCC ACA TC - #A TAT GAT CTT GGG TAT 644Glu Gly Val Thr Val Leu Ser Leu Pro Thr Se - #r Tyr Asp Leu Gly Tyr# 175- GTG AGG CTT GGT GAC CCC ATA CCC GCT ATA GG - #G CTT GAC CCA AAA ATG 692Val Arg Leu Gly Asp Pro Ile Pro Ala Ile Gl - #y Leu Asp Pro Lys Met# 190- GTA GCA ACA TGT GAC AGC AGT GAC AGG CCC AG - #A GTC TAC ACC ATA ACT 740Val Ala Thr Cys Asp Ser Ser Asp Arg Pro Ar - #g Val Tyr Thr Ile Thr# 205- GCA GCT GAT GAT TAC CAA TTC TCA TCA CAG TA - #C CAA ACA GGT GGG GTA 788Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gln Ty - #r Gln Thr Gly Gly Val210 2 - #15 2 - #20 2 -#25- ACA ATC ACC CTG TTC TCA GCC AAC ATT GAT GC - #C ATC ACA AGC CTC AGC 836Thr Ile Thr Leu Phe Ser Ala Asn Ile Asp Al - #a Ile Thr Ser Leu Ser# 240- GTT GGG GGA GAG CTC GTG TTT AAA ACA AGC GT - #C CAC AGC CTT GTA CTG 884Val Gly Gly Glu Leu Val Phe Lys Thr Ser Va - #l His Ser Leu Val Leu# 255- GGC GCC ACC ATC TAC CTT ATA GGC TTT GAT GG - #G TCT GCG GTA ATC ACT 932Gly Ala Thr Ile Tyr Leu Ile Gly Phe Asp Gl - #y Ser Ala Val Ile Thr# 270- AGA GCT GTG GCC GCA AAC AAT GGG CTG ACG AC - #C GGC ACC GAC AAT CTT 980Arg Ala Val Ala Ala Asn Asn Gly Leu Thr Th - #r Gly Thr Asp Asn Leu# 285- ATG CCA TTC AAT CTT GTG ATT CCA ACC AAC GA - #G ATA ACC CAG CCA ATC1028Met Pro Phe Asn Leu Val Ile Pro Thr Asn Gl - #u Ile Thr Gln Pro Ile290 2 - #95 3 - #00 3 -#05- ACA TCC ATC AAA CTG GAG ATA GTG ACC TCC AA - #A AGT GGT GGT CAG GAA1076Thr Ser Ile Lys Leu Glu Ile Val Thr Ser Ly - #s Ser Gly Gly Gln Glu# 320- GGG GAC CAG ATG TCA TGG TCG GCA AGT GGG AG - #C CTA GCA GTG ACG ATT1124Gly Asp Gln Met Ser Trp Ser Ala Ser Gly Se - #r Leu Ala Val Thr Ile# 335- CAT GGT GGC AAC TAT CCA GGG GCC CTC CGT CC - #C GTC ACA CTA GTA GCC1172His Gly Gly Asn Tyr Pro Gly Ala Leu Arg Pr - #o Val Thr Leu Val Ala# 350- TAC GAA AGA GTG GCA ACA GGA TCT GTC GTT AC - #G GTC GCT GGG GTG AGC1220Tyr Glu Arg Val Ala Thr Gly Ser Val Val Th - #r Val Ala Gly Val Ser# 365- AAC TTC GAG CTG ATC CCA AAT CCT GAA CTA GC - #A AAG AAC CTG GTT ACA1268Asn Phe Glu Leu Ile Pro Asn Pro Glu Leu Al - #a Lys Asn Leu Val Thr370 3 - #75 3 - #80 3 -#85- GAA TAC GGC CGA TTT GAC CCA GGA GCC ATG AA - #C TAC ACA AAA TTG ATA1316Glu Tyr Gly Arg Phe Asp Pro Gly Ala Met As - #n Tyr Thr Lys Leu Ile# 400- CTG AGT GAG AGG GAC CGC CTT GGC ATC AAG AC - #A GTC TGG CCG ACA AGG1364Leu Ser Glu Arg Asp Arg Leu Gly Ile Lys Th - #r Val Trp Pro Thr Arg# 415- GAG TAC ACC GAC TTT CGT GAG TAC TTC ATG GA - #G GTG GCC GAC CTC AGC1412Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Met Gl - #u Val Ala Asp Leu Ser# 430- TCT CCC CTG AAG ATT GCA GGA GCA TTT GGC TT - #C AAA GAC ATA ATC CGG1460Ser Pro Leu Lys Ile Ala Gly Ala Phe Gly Ph - #e Lys Asp Ile Ile Arg# 445- GCC ATA AGG AGG ATA GCT GTG CCG GTG GTC TC - #C ACA TTG TTC CCA CCT1508Ala Ile Arg Arg Ile Ala Val Pro Val Val Se - #r Thr Leu Phe Pro Pro450 4 - #55 4 - #60 4 -#65- GCC GCT CCC CTG GCC CAT GCA ATT GGG GAA GG - #T GTA GAC TAC CTG CTG1556Ala Ala Pro Leu Ala His Ala Ile Gly Glu Gl - #y Val Asp Tyr Leu Leu# 480- GGT GAT GAG GCA CAG GCT GCT TCA GGA ACT GC - #T CGA GCC GCG TCA GGA1604Gly Asp Glu Ala Gln Ala Ala Ser Gly Thr Al - #a Arg Ala Ala Ser Gly# 495- AAA GCA AGG GCT GCC TCA GGC CGC ATA AGG CA - #G CTG ACT CTC GCC GCC1652Lys Ala Arg Ala Ala Ser Gly Arg Ile Arg Gl - #n Leu Thr Leu Ala Ala# 510- GAC AAG GGG TAC GAG GTA GTC GCG AAT CTA TT - #C CAG GTG CCC CAG AAT1700Asp Lys Gly Tyr Glu Val Val Ala Asn Leu Ph - #e Gln Val Pro Gln Asn# 525- CCC GTA GTC GAC GGG ATT CTT GCT TCA CCC GG - #G ATA CTC CGC GGT GCA1748Pro Val Val Asp Gly Ile Leu Ala Ser Pro Gl - #y Ile Leu Arg Gly Ala530 5 - #35 5 - #40 5 -#45- CAC AAC CTC GAC TGC GTG TTA AGA GAG GGC GC - #C ACG CTA TTC CCT GTG1796His Asn Leu Asp Cys Val Leu Arg Glu Gly Al - #a Thr Leu Phe Pro Val# 560- GTC ATC ACG ACA GTG GAA GAC GCC ATG ACA CC - #C AAA GCA CTA AAC AGC1844Val Ile Thr Thr Val Glu Asp Ala Met Thr Pr - #o Lys Ala Leu Asn Ser# 575- AAA ATG TTT GCT GTC ATT GAA GGC GTG CGA GA - #G GAC CTC CAA CCT CCA1892Lys Met Phe Ala Val Ile Glu Gly Val Arg Gl - #u Asp Leu Gln Pro Pro# 590- TCT CAA AGA GGA TCC TTC ATA CGA ACT CTC TC - #C GGA CAC AGA GTC TAT1940Ser Gln Arg Gly Ser Phe Ile Arg Thr Leu Se - #r Gly His Arg Val Tyr# 605- GGA TAT GCT CCA GAT GGG GTA CTT CCA CTG GA - #G ACT GGG AGA GAC TAC1988Gly Tyr Ala Pro Asp Gly Val Leu Pro Leu Gl - #u Thr Gly Arg Asp Tyr610 6 - #15 6 - #20 6 -#25- ACC GTT GTC CCA ATA GAT GAT GTC TGG GAC GA - #C AGC ATT ATG CTG TCC2036Thr Val Val Pro Ile Asp Asp Val Trp Asp As - #p Ser Ile Met Leu Ser# 640- AAA GAC CCC ATA CCT CCT ATT GTG GGA AAC AG - #T GGA AAC CTA GCC ATA2084Lys Asp Pro Ile Pro Pro Ile Val Gly Asn Se - #r Gly Asn Leu Ala Ile# 655- GCT TAC ATG GAT GTG TTT CGA CCC AAA GTC CC - #C ATC CAT GTG GCC ATG2132Ala Tyr Met Asp Val Phe Arg Pro Lys Val Pr - #o Ile His Val Ala Met# 670- ACG GGA GCC CTC AAC GCT TGT GGC GAG ATT GA - #G AAA ATA AGC TTT AGA2180Thr Gly Ala Leu Asn Ala Cys Gly Glu Ile Gl - #u Lys Ile Ser Phe Arg# 685- AGC ACC AAG CTC GCC ACC GCA CAC CGG CTT GG - #C CTC AAG TTG GCT GGT2228Ser Thr Lys Leu Ala Thr Ala His Arg Leu Gl - #y Leu Lys Leu Ala Gly690 6 - #95 7 - #00 7 -#05- CCC GGA GCA TTT GAT GTA AAC ACC GGG CCC AA - #C TGG GCA ACG TTC ATC2276Pro Gly Ala Phe Asp Val Asn Thr Gly Pro As - #n Trp Ala Thr Phe Ile# 720- AAA CGT TTC CCT CAC AAT CCA CGC GAC TGG GA - #C AGG CTC CCC TAC CTC2324Lys Arg Phe Pro His Asn Pro Arg Asp Trp As - #p Arg Leu Pro Tyr Leu# 735- AAC CTT CCA TAC CTT CCA CCC AAT GCA GGA CG - #C CAG TAC CAC CTC GCC2372Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gly Ar - #g Gln Tyr His Leu Ala# 750- ATG GCC GCA TCA GAG TTC AAG GAG ACC CCT GA - #A CTC GAG AGC GCC GTC2420Met Ala Ala Ser Glu Phe Lys Glu Thr Pro Gl - #u Leu Glu Ser Ala Val# 765- AGG GCC ATG GAA GCA GCA GCC AGT GTA GAC CC - #A CTG TTC CAA TCT GCA2468Arg Ala Met Glu Ala Ala Ala Ser Val Asp Pr - #o Leu Phe Gln Ser Ala770 7 - #75 7 - #80 7 -#85- CTC AGT GTG TTC ATG TGG CTG GAA GAG AAT GG - #G ATT GTG ACT GAC ATG2516Leu Ser Val Phe Met Trp Leu Glu Glu Asn Gl - #y Ile Val Thr Asp Met# 800- GCC AAC TTC GCA CTC AGC GAC CCG AAC GCC CA - #T CGG ATG CGA AAC TTT2564Ala Asn Phe Ala Leu Ser Asp Pro Asn Ala Hi - #s Arg Met Arg Asn Phe# 815- CTT GCA AAC GCA CCA CAA GCA GGT AGC AAG TC - #T CAA AGG GCC AAA TAC2612Leu Ala Asn Ala Pro Gln Ala Gly Ser Lys Se - #r Gln Arg Ala Lys Tyr# 830- GGG ACA GCA GGC TAC GGA GTG GAG GCC CGG GG - #C CCC ACA CCA GAA GAA2660Gly Thr Ala Gly Tyr Gly Val Glu Ala Arg Gl - #y Pro Thr Pro Glu Glu# 845- GCA CAG AGG GAA AAA GAC ACA CGG ATC TCA AA - #G AAG ATG GAG ACC ATG2708Ala Gln Arg Glu Lys Asp Thr Arg Ile Ser Ly - #s Lys Met Glu Thr Met850 8 - #55 8 - #60 8 -#65- GGC ATC TAC TTT GCA ACA CCA GAA TGG GTA GC - #A CTC AAT GGG CAC CGA2756Gly Ile Tyr Phe Ala Thr Pro Glu Trp Val Al - #a Leu Asn Gly His Arg# 880- GGG CCA AGC CCC GGC CAG CTA AAG TAC TGG CA - #G AAC ACA CGA GAA ATA2804Gly Pro Ser Pro Gly Gln Leu Lys Tyr Trp Gl - #n Asn Thr Arg Glu Ile# 895- CCG GAC CCA AAC GAG GAC TAT CTA GAC TAC GT - #G CAT GCA GAG AAG AGC2852Pro Asp Pro Asn Glu Asp Tyr Leu Asp Tyr Va - #l His Ala Glu Lys Ser# 910- CGG TTG GCA TCA GAA GAA CAA ATC CTA AGG GC - #A GCT ACG TCG ATC TAC2900Arg Leu Ala Ser Glu Glu Gln Ile Leu Arg Al - #a Ala Thr Ser Ile Tyr# 925- GGG GCT CCA GGA CAG GCA GAG CCA CCC CAA GC - #T TTC ATA GAC GAA GTT2948Gly Ala Pro Gly Gln Ala Glu Pro Pro Gln Al - #a Phe Ile Asp Glu Val930 9 - #35 9 - #40 9 -#45- GCC AAA GTC TAT GAA ATC AAC CAT GGA CGT GG - #C CCA AAC CAA GAA CAG2996Ala Lys Val Tyr Glu Ile Asn His Gly Arg Gl - #y Pro Asn Gln Glu Gln# 960- ATG AAA GAT CTG CTC TTG ACT GCG ATG GAG AT - #G AAG CAT CGC AAT CCC3044Met Lys Asp Leu Leu Leu Thr Ala Met Glu Me - #t Lys His Arg Asn Pro# 975- AGG CGG GCT CCA CCA AAG CCC AAG CCA AGA CC - #C AAC GCT CCA ACG CAG3092Arg Arg Ala Pro Pro Lys Pro Lys Pro Arg Pr - #o Asn Ala Pro Thr Gln# 990- AGA CCC CCT GGT CGG CTG GGC CGC TGG ATC AG - #G ACT GTC TCT GAT GAG3140Arg Pro Pro Gly Arg Leu Gly Arg Trp Ile Ar - #g Thr Val Ser Asp Glu# 10050- GAC CTT GAG TGAGGCTCCT GGGAGTCTCC CGACACCACC CGCGCAGGC - #G3189Asp Leu Glu1010# 3230 CTTA CAACATCCCA AATTGGATCC G- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:- Met Thr Asn Leu Gln Asp Gln Thr Gln Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Asn Gly Asn Tyr# 80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asp Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Thr Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Lys Thr Se - #r Val His Ser Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Ser Ala Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Thr Gly Thr Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Lys Leu Glu Ile Val Thr Se - #r Lys Ser Gly Gly Gln305 3 - #10 3 - #15 3 -#20- Glu Gly Asp Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp Arg Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Ser Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Ile Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Ile Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Ser Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Thr Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ar - #g Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ar - #g Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:13:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 3180 base (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown- (ii) MOLECULE TYPE: DNA (genomic)- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 64..3099- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:- GAATTCCTCC TTCTACAACG CTATCATTGA TGGTTAGTAG AGATCAGACA AA - #CGATCGCA 60- GCG ATG ACA AAC CTG CAA GAT CAA ACC CAC CA - #G ATT GTT CCG TTC ATA 108#His Gln Ile Val Pro Phe IleGln Thr# 10250- CGG AGC CTT CTG ATG CCA ACA ACC GGA CCG GC - #G TCC ATT CCG GAC GAC 156Arg Ser Leu Leu Met Pro Thr Thr Gly Pro Al - #a Ser Ile Pro Asp Asp# 10405- ACC CTG GAG AAG CAC ACT CTC AGG TCA GAG AC - #C TCG ACC TAC AAT TTG 204Thr Leu Glu Lys His Thr Leu Arg Ser Glu Th - #r Ser Thr Tyr Asn Leu# 10550- ACT GTG GGG GAC ACA GGG TCA GGG CTA ATT GT - #C TTT TTC CCT GGA TTC 252Thr Val Gly Asp Thr Gly Ser Gly Leu Ile Va - #l Phe Phe Pro Gly Phe# 10751065 - # 1070- CCT GGC TCA ATT GTG GGT GCT CAC TAC ACA CT - #G CAG AGC AGT GGG AAC 300Pro Gly Ser Ile Val Gly Ala His Tyr Thr Le - #u Gln Ser Ser Gly Asn# 10905- TAC AAG TTC GAT CAG ATG CTC CTG ACT GCC CA - #G AAC CTA CCG GCC AGC 348Tyr Lys Phe Asp Gln Met Leu Leu Thr Ala Gl - #n Asn Leu Pro Ala Ser# 11050- TAC AAC TAC TGC AGG CTA GTG AGT CGG AGT CT - #C ACA GTA AGG TCA AGC 396Tyr Asn Tyr Cys Arg Leu Val Ser Arg Ser Le - #u Thr Val Arg Ser Ser# 11205- ACA CTC CCT GGT GGC GTT TAT GCA CTA AAC GG - #C ACC ATA AAC GCC GTG 444Thr Leu Pro Gly Gly Val Tyr Ala Leu Asn Gl - #y Thr Ile Asn Ala Val# 11350- ACC TTC CAA GGA AGC CTG AGT GAA CTG ACA GA - #T GTT AGC TAC AAC GGG 492Thr Phe Gln Gly Ser Leu Ser Glu Leu Thr As - #p Val Ser Tyr Asn Gly# 11551145 - # 1150- TTG ATG TCT GCA ACA GCC AAC ATC AAC GAC AA - #A ATT GGG AAC GTC CTA 540Leu Met Ser Ala Thr Ala Asn Ile Asn Asp Ly - #s Ile Gly Asn Val Leu# 11705- GTA GGG GAA GGG GTA ACC GTC CTC AGC TTA CC - #C ACA TCA TAT GAT CTT 588Val Gly Glu Gly Val Thr Val Leu Ser Leu Pr - #o Thr Ser Tyr Asp Leu# 11850- GGG TAT GTG AGG CTT GGT GAC CCC ATA CCC GC - #T ATA GGG CTT GAC CCA 636Gly Tyr Val Arg Leu Gly Asp Pro Ile Pro Al - #a Ile Gly Leu Asp Pro# 12005- AAA ATG GTA GCA ACA TGT GAC AGC AGT GAC AG - #G CCC AGA GTC TAC ACC 684Lys Met Val Ala Thr Cys Asp Ser Ser Asp Ar - #g Pro Arg Val Tyr Thr# 12150- ATA ACT GCA GCC GAT AAT TAC CAA TTC TCA TC - #A CAG TAC CAA ACA GGT 732Ile Thr Ala Ala Asp Asn Tyr Gln Phe Ser Se - #r Gln Tyr Gln Thr Gly# 12351225 - # 1230- GGG GTA ACA ATC ACA CTG TTC TCA GCC AAC AT - #T GAT GCC ATC ACA AGT 780Gly Val Thr Ile Thr Leu Phe Ser Ala Asn Il - #e Asp Ala Ile Thr Ser# 12505- CTC AGC GTT GGG GGA GAG CTC GTG TTC AAA AC - #A AGC GTC CAA AGC CTT 828Leu Ser Val Gly Gly Glu Leu Val Phe Lys Th - #r Ser Val Gln Ser Leu# 12650- GTA CTG GGC GCC ACC ATC TAC CTT ATA GGC TT - #T GAT GGG ACT GCG GTA 876Val Leu Gly Ala Thr Ile Tyr Leu Ile Gly Ph - #e Asp Gly Thr Ala Val# 12805- ATC ACC AGA GCT GTG GCC GCA AAC AAT GGG CT - #G ACG GCC GGC ATC GAC 924Ile Thr Arg Ala Val Ala Ala Asn Asn Gly Le - #u Thr Ala Gly Ile Asp# 12950- AAT CTT ATG CCA TTC AAT CTT GTG ATT CCA AC - #C AAT GAG ATA ACC CAG 972Asn Leu Met Pro Phe Asn Leu Val Ile Pro Th - #r Asn Glu Ile Thr Gln# 13151305 - # 1310- CCA ATC ACA TCC ATC ATA CTG GAG ATA GTG AC - #C TCC AAA AGT GAT GGT1020Pro Ile Thr Ser Ile Ile Leu Glu Ile Val Th - #r Ser Lys Ser Asp Gly# 13305- CAG GCA GGG GAA CAG ATG TCA TGG TCG GCA AG - #T GGG AGC CTA GCA GTG1068Gln Ala Gly Glu Gln Met Ser Trp Ser Ala Se - #r Gly Ser Leu Ala Val# 13450- ACG ATC CAT GGT GGC AAC TAT CCA GGA GCC CT - #C CGT CCC GTC ACA CTA1116Thr Ile His Gly Gly Asn Tyr Pro Gly Ala Le - #u Arg Pro Val Thr Leu# 13605- GTG GCC TAC GAA AGA GTG GCA ACA GGA TCT GT - #C GTT ACG GTC GCT GGG1164Val Ala Tyr Glu Arg Val Ala Thr Gly Ser Va - #l Val Thr Val Ala Gly# 13750- GTG AGC AAC TTC GAG CTG ATC CCA AAT CCT GA - #A CTA GCA AAG AAC CTG1212Val Ser Asn Phe Glu Leu Ile Pro Asn Pro Gl - #u Leu Ala Lys Asn Leu# 13951385 - # 1390- GTT ACA GAA TAC GGC CGA TTT GAC CCA GGA GC - #C ATG AAC TAC ACG AAA1260Val Thr Glu Tyr Gly Arg Phe Asp Pro Gly Al - #a Met Asn Tyr Thr Lys# 14105- TTG ATA CTG AGT GAG AGG GAC CAC CTT GGC AT - #C AAG ACC GTC TGG CCA1308Leu Ile Leu Ser Glu Arg Asp His Leu Gly Il - #e Lys Thr Val Trp Pro# 14250- ACA AGG GAG TAC ACT GAC TTT CGT GAG TAC TT - #C ATG GAG GTG GCC GAC1356Thr Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Ph - #e Met Glu Val Ala Asp# 14405- CTC AAC TCT CCC CTG AAG ATT GCA GGA GCA TT - #T GGC TTC AAA GAC ATA1404Leu Asn Ser Pro Leu Lys Ile Ala Gly Ala Ph - #e Gly Phe Lys Asp Ile# 14550- ATC CGG GCC ATA AGG AGG ATA GCT GTA CCG GT - #G GTC TCT ACA TTG TTC1452Ile Arg Ala Ile Arg Arg Ile Ala Val Pro Va - #l Val Ser Thr Leu Phe# 14751465 - # 1470- CCA CCT GCC GCT CCT CTA GCC CAT GCA ATT GG - #G GAA GGT GTA GAC TAC1500Pro Pro Ala Ala Pro Leu Ala His Ala Ile Gl - #y Glu Gly Val Asp Tyr# 14905- CTA CTG GGC GAT GAG GCA CAG GCT GCT TCA GG - #A ACC GCT CGA GCC GCG1548Leu Leu Gly Asp Glu Ala Gln Ala Ala Ser Gl - #y Thr Ala Arg Ala Ala# 15050- TCA GGA AAA GCA AGG GCT GCC TCA GGC CGC AT - #A AGG CAG CTG ACT CTC1596Ser Gly Lys Ala Arg Ala Ala Ser Gly Arg Il - #e Arg Gln Leu Thr Leu# 15205- GCC GCC GAC AAG GGG TAC GAG GTA GTC GCG AA - #T CTA TTC CAG GTG CCC1644Ala Ala Asp Lys Gly Tyr Glu Val Val Ala As - #n Leu Phe Gln Val Pro# 15350- CAG AAT CCC GTA GTC GAC GGG ATT CTT GCT TC - #A CCC GGG ATA CTT CGC1692Gln Asn Pro Val Val Asp Gly Ile Leu Ala Se - #r Pro Gly Ile Leu Arg# 15551545 - # 1550- GGT GCA CAC AAC CTC GAC TGC GTG CTA AGA GA - #G GGT GCC ACG CTA TTC1740Gly Ala His Asn Leu Asp Cys Val Leu Arg Gl - #u Gly Ala Thr Leu Phe# 15705- CCT GTG GTC ATT ACG ACA GTG GAA GAC GCC AT - #G ACA CCC AAA GCA CTG1788Pro Val Val Ile Thr Thr Val Glu Asp Ala Me - #t Thr Pro Lys Ala Leu# 15850- AAC AGC AAA ATG TTT GCT GTC ATT GAA GGC GT - #G CGA GAA GAC CTC CAA1836Asn Ser Lys Met Phe Ala Val Ile Glu Gly Va - #l Arg Glu Asp Leu Gln# 16005- CCT CCA TCT CAA AGA GGA TCC TTC ATA CGA AC - #T CTC TCC GGA CAC AGA1884Pro Pro Ser Gln Arg Gly Ser Phe Ile Arg Th - #r Leu Ser Gly His Arg# 16150- GTC TAT GGA TAT GCT CCA GAT GGG GTA CTT CC - #A CTG GAG ACT GGG AGA1932Val Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pr - #o Leu Glu Thr Gly Arg# 16351625 - # 1630- GAC TAC ACC GTT GTC CCA ATA GAT GAT GTC TG - #G GAC GAC AGC ATT ATG1980Asp Tyr Thr Val Val Pro Ile Asp Asp Val Tr - #p Asp Asp Ser Ile Met# 16505- CTG TCC AAG GAC CCC ATA CCT CCT ATT GTG GG - #A AAC AGT GGA AAC CTA2028Leu Ser Lys Asp Pro Ile Pro Pro Ile Val Gl - #y Asn Ser Gly Asn Leu# 16650- GCC ATA GCT TAC ATG GAT GTG TTT CGA CCC AA - #A GTC CCC ATC CAT GTG2076Ala Ile Ala Tyr Met Asp Val Phe Arg Pro Ly - #s Val Pro Ile His Val# 16805- GCC ATG ACG GGA GCC CTC AAC GCT TGT GGC GA - #G ATT GAG AAA ATA AGC2124Ala Met Thr Gly Ala Leu Asn Ala Cys Gly Gl - #u Ile Glu Lys Ile Ser# 16950- TTC AGA AGC ACC AAG CTC GCC ACC GCA CAC CG - #G CTT GGC CTC AAG TTG2172Phe Arg Ser Thr Lys Leu Ala Thr Ala His Ar - #g Leu Gly Leu Lys Leu# 17151705 - # 1710- GCT GGT CCC GGA GCA TTC GAT GTA AAC ACC GG - #G CCC AAC TGG GCA ACG2220Ala Gly Pro Gly Ala Phe Asp Val Asn Thr Gl - #y Pro Asn Trp Ala Thr# 17305- TTC ATC AAA CGT TTC CCT CAC AAT CCA CGC GA - #C TGG GAC AGG CTC CCC2268Phe Ile Lys Arg Phe Pro His Asn Pro Arg As - #p Trp Asp Arg Leu Pro# 17450- TAC CTC AAC CTT CCA TAC CTT CCA CCC AAT GC - #A GGA CGC CAG TAC CAC2316Tyr Leu Asn Leu Pro Tyr Leu Pro Pro Asn Al - #a Gly Arg Gln Tyr His# 17605- CTT GCC ATG GCT GCA TCA GAG TTT AAA GAG AC - #C CCT GAA CTC GAG AGC2364Leu Ala Met Ala Ala Ser Glu Phe Lys Glu Th - #r Pro Glu Leu Glu Ser# 17750- GCC GTC AGA GCC ATG GAA GCA GCA GCC AAT GT - #G GAC CCA CTG TTC CAA2412Ala Val Arg Ala Met Glu Ala Ala Ala Asn Va - #l Asp Pro Leu Phe Gln# 17951785 - # 1790- TCT GCA CTC AGT GTG TTC ATG TGG CTG GAA GA - #G AAT GGG ATT GTG GCT2460Ser Ala Leu Ser Val Phe Met Trp Leu Glu Gl - #u Asn Gly Ile Val Ala# 18105- GAC ATG GCC AAT TTC GCA CTC AGC GAC CCG AA - #C GCC CAT CGG ATG CGA2508Asp Met Ala Asn Phe Ala Leu Ser Asp Pro As - #n Ala His Arg Met Arg# 18250- AAT TTT CTT GCA AAC GCA CCA CAA GCA GGC AG - #C AAG TCG CAA AGG GCC2556Asn Phe Leu Ala Asn Ala Pro Gln Ala Gly Se - #r Lys Ser Gln Arg Ala# 18405- AAG TAC GGG ACA GCA GGC TAC GGA GTG GAG GC - #C CGG GGC CCC ACA CCA2604Lys Tyr Gly Thr Ala Gly Tyr Gly Val Glu Al - #a Arg Gly Pro Thr Pro# 18550- GAG GAA GCA CAG AGG GAA AAA GAC ACA CGG AT - #C TCA AAG AAG ATG GAG2652Glu Glu Ala Gln Arg Glu Lys Asp Thr Arg Il - #e Ser Lys Lys Met Glu# 18751865 - # 1870- ACC ATG GGC ATC TAC TTT GCA ACA CCA GAA TG - #G GTA GCA CTC AAT GGG2700Thr Met Gly Ile Tyr Phe Ala Thr Pro Glu Tr - #p Val Ala Leu Asn Gly# 18905- CAC CGA GGG CCA AGC CCC GGC CAG CTA AAG TA - #C TGG CAG AAC ACA CGA2748His Arg Gly Pro Ser Pro Gly Gln Leu Lys Ty - #r Trp Gln Asn Thr Arg# 19050- GAA ATA CCG GAC CCA AAC GAG GAC TAT CTA GA - #C TAC GTG CAT GCA GAG2796Glu Ile Pro Asp Pro Asn Glu Asp Tyr Leu As - #p Tyr Val His Ala Glu# 19205- AAG AGC CGG TTG GCA TCA GAA GAA CAA ATC CT - #A AAG GCA GCT ACG TCG2844Lys Ser Arg Leu Ala Ser Glu Glu Gln Ile Le - #u Lys Ala Ala Thr Ser# 19350- ATC TAC GGG GCT CCA GGA CAG GCA GAG CCA CC - #C CAA GCT TTC ATA GAC2892Ile Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pr - #o Gln Ala Phe Ile Asp# 19551945 - # 1950- GAA GTT GCC AAA GTC TAT GAA ATC AAC CAT GG - #A CGT GGC CCT AAC CAA2940Glu Val Ala Lys Val Tyr Glu Ile Asn His Gl - #y Arg Gly Pro Asn Gln# 19705- GAA CAG ATG AAA GAT CTG CTC TTG ACT GCA AT - #G GAG ATG AAG CAT CGC2988Glu Gln Met Lys Asp Leu Leu Leu Thr Ala Me - #t Glu Met Lys His Arg# 19850- AAC CCC AGG CGG GCT CCA CCA AAG CCC AAG CC - #A AAA CCC AAT GCT CCA3036Asn Pro Arg Arg Ala Pro Pro Lys Pro Lys Pr - #o Lys Pro Asn Ala Pro# 20005- ACA CAG AGA CCC CCT GGT CGG CTG GGC CGC TG - #G ATC AGG ACC GTC TCT3084Thr Gln Arg Pro Pro Gly Arg Leu Gly Arg Tr - #p Ile Arg Thr Val Ser# 20150- GAT GAG GAC CTT GAG TGAGGCCCCT GGGGGTCTCC CGACACCAC - #C CGCGCAGGCG3139Asp Glu Asp Leu Glu2020# 3180 CTTA CAACATCCCA AATTGGATCC G- (2) INFORMATION FOR SEQ ID NO:14:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 1012 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:- Met Thr Asn Leu Gln Asp Gln Thr His Gln Il - #e Val Pro Phe Ile Arg# 15- Ser Leu Leu Met Pro Thr Thr Gly Pro Ala Se - #r Ile Pro Asp Asp Thr# 30- Leu Glu Lys His Thr Leu Arg Ser Glu Thr Se - #r Thr Tyr Asn Leu Thr# 45- Val Gly Asp Thr Gly Ser Gly Leu Ile Val Ph - #e Phe Pro Gly Phe Pro# 60- Gly Ser Ile Val Gly Ala His Tyr Thr Leu Gl - #n Ser Ser Gly Asn Tyr# 80- Lys Phe Asp Gln Met Leu Leu Thr Ala Gln As - #n Leu Pro Ala Ser Tyr# 95- Asn Tyr Cys Arg Leu Val Ser Arg Ser Leu Th - #r Val Arg Ser Ser Thr# 110- Leu Pro Gly Gly Val Tyr Ala Leu Asn Gly Th - #r Ile Asn Ala Val Thr# 125- Phe Gln Gly Ser Leu Ser Glu Leu Thr Asp Va - #l Ser Tyr Asn Gly Leu# 140- Met Ser Ala Thr Ala Asn Ile Asn Asp Lys Il - #e Gly Asn Val Leu Val145 1 - #50 1 - #55 1 -#60- Gly Glu Gly Val Thr Val Leu Ser Leu Pro Th - #r Ser Tyr Asp Leu Gly# 175- Tyr Val Arg Leu Gly Asp Pro Ile Pro Ala Il - #e Gly Leu Asp Pro Lys# 190- Met Val Ala Thr Cys Asp Ser Ser Asp Arg Pr - #o Arg Val Tyr Thr Ile# 205- Thr Ala Ala Asp Asn Tyr Gln Phe Ser Ser Gl - #n Tyr Gln Thr Gly Gly# 220- Val Thr Ile Thr Leu Phe Ser Ala Asn Ile As - #p Ala Ile Thr Ser Leu225 2 - #30 2 - #35 2 -#40- Ser Val Gly Gly Glu Leu Val Phe Lys Thr Se - #r Val Gln Ser Leu Val# 255- Leu Gly Ala Thr Ile Tyr Leu Ile Gly Phe As - #p Gly Thr Ala Val Ile# 270- Thr Arg Ala Val Ala Ala Asn Asn Gly Leu Th - #r Ala Gly Ile Asp Asn# 285- Leu Met Pro Phe Asn Leu Val Ile Pro Thr As - #n Glu Ile Thr Gln Pro# 300- Ile Thr Ser Ile Ile Leu Glu Ile Val Thr Se - #r Lys Ser Asp Gly Gln305 3 - #10 3 - #15 3 -#20- Ala Gly Glu Gln Met Ser Trp Ser Ala Ser Gl - #y Ser Leu Ala Val Thr# 335- Ile His Gly Gly Asn Tyr Pro Gly Ala Leu Ar - #g Pro Val Thr Leu Val# 350- Ala Tyr Glu Arg Val Ala Thr Gly Ser Val Va - #l Thr Val Ala Gly Val# 365- Ser Asn Phe Glu Leu Ile Pro Asn Pro Glu Le - #u Ala Lys Asn Leu Val# 380- Thr Glu Tyr Gly Arg Phe Asp Pro Gly Ala Me - #t Asn Tyr Thr Lys Leu385 3 - #90 3 - #95 4 -#00- Ile Leu Ser Glu Arg Asp His Leu Gly Ile Ly - #s Thr Val Trp Pro Thr# 415- Arg Glu Tyr Thr Asp Phe Arg Glu Tyr Phe Me - #t Glu Val Ala Asp Leu# 430- Asn Ser Pro Leu Lys Ile Ala Gly Ala Phe Gl - #y Phe Lys Asp Ile Ile# 445- Arg Ala Ile Arg Arg Ile Ala Val Pro Val Va - #l Ser Thr Leu Phe Pro# 460- Pro Ala Ala Pro Leu Ala His Ala Ile Gly Gl - #u Gly Val Asp Tyr Leu465 4 - #70 4 - #75 4 -#80- Leu Gly Asp Glu Ala Gln Ala Ala Ser Gly Th - #r Ala Arg Ala Ala Ser# 495- Gly Lys Ala Arg Ala Ala Ser Gly Arg Ile Ar - #g Gln Leu Thr Leu Ala# 510- Ala Asp Lys Gly Tyr Glu Val Val Ala Asn Le - #u Phe Gln Val Pro Gln# 525- Asn Pro Val Val Asp Gly Ile Leu Ala Ser Pr - #o Gly Ile Leu Arg Gly# 540- Ala His Asn Leu Asp Cys Val Leu Arg Glu Gl - #y Ala Thr Leu Phe Pro545 5 - #50 5 - #55 5 -#60- Val Val Ile Thr Thr Val Glu Asp Ala Met Th - #r Pro Lys Ala Leu Asn# 575- Ser Lys Met Phe Ala Val Ile Glu Gly Val Ar - #g Glu Asp Leu Gln Pro# 590- Pro Ser Gln Arg Gly Ser Phe Ile Arg Thr Le - #u Ser Gly His Arg Val# 605- Tyr Gly Tyr Ala Pro Asp Gly Val Leu Pro Le - #u Glu Thr Gly Arg Asp# 620- Tyr Thr Val Val Pro Ile Asp Asp Val Trp As - #p Asp Ser Ile Met Leu625 6 - #30 6 - #35 6 -#40- Ser Lys Asp Pro Ile Pro Pro Ile Val Gly As - #n Ser Gly Asn Leu Ala# 655- Ile Ala Tyr Met Asp Val Phe Arg Pro Lys Va - #l Pro Ile His Val Ala# 670- Met Thr Gly Ala Leu Asn Ala Cys Gly Glu Il - #e Glu Lys Ile Ser Phe# 685- Arg Ser Thr Lys Leu Ala Thr Ala His Arg Le - #u Gly Leu Lys Leu Ala# 700- Gly Pro Gly Ala Phe Asp Val Asn Thr Gly Pr - #o Asn Trp Ala Thr Phe705 7 - #10 7 - #15 7 -#20- Ile Lys Arg Phe Pro His Asn Pro Arg Asp Tr - #p Asp Arg Leu Pro Tyr# 735- Leu Asn Leu Pro Tyr Leu Pro Pro Asn Ala Gl - #y Arg Gln Tyr His Leu# 750- Ala Met Ala Ala Ser Glu Phe Lys Glu Thr Pr - #o Glu Leu Glu Ser Ala# 765- Val Arg Ala Met Glu Ala Ala Ala Asn Val As - #p Pro Leu Phe Gln Ser# 780- Ala Leu Ser Val Phe Met Trp Leu Glu Glu As - #n Gly Ile Val Ala Asp785 7 - #90 7 - #95 8 -#00- Met Ala Asn Phe Ala Leu Ser Asp Pro Asn Al - #a His Arg Met Arg Asn# 815- Phe Leu Ala Asn Ala Pro Gln Ala Gly Ser Ly - #s Ser Gln Arg Ala Lys# 830- Tyr Gly Thr Ala Gly Tyr Gly Val Glu Ala Ar - #g Gly Pro Thr Pro Glu# 845- Glu Ala Gln Arg Glu Lys Asp Thr Arg Ile Se - #r Lys Lys Met Glu Thr# 860- Met Gly Ile Tyr Phe Ala Thr Pro Glu Trp Va - #l Ala Leu Asn Gly His865 8 - #70 8 - #75 8 -#80- Arg Gly Pro Ser Pro Gly Gln Leu Lys Tyr Tr - #p Gln Asn Thr Arg Glu# 895- Ile Pro Asp Pro Asn Glu Asp Tyr Leu Asp Ty - #r Val His Ala Glu Lys# 910- Ser Arg Leu Ala Ser Glu Glu Gln Ile Leu Ly - #s Ala Ala Thr Ser Ile# 925- Tyr Gly Ala Pro Gly Gln Ala Glu Pro Pro Gl - #n Ala Phe Ile Asp Glu# 940- Val Ala Lys Val Tyr Glu Ile Asn His Gly Ar - #g Gly Pro Asn Gln Glu945 9 - #50 9 - #55 9 -#60- Gln Met Lys Asp Leu Leu Leu Thr Ala Met Gl - #u Met Lys His Arg Asn# 975- Pro Arg Arg Ala Pro Pro Lys Pro Lys Pro Ly - #s Pro Asn Ala Pro Thr# 990- Gln Arg Pro Pro Gly Arg Leu Gly Arg Trp Il - #e Arg Thr Val Ser Asp# 10050- Glu Asp Leu Glu 1010- (2) INFORMATION FOR SEQ ID NO:15:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 7 amino (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: peptide- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:- Ser Trp Ser Ala Ser Gly Ser1 5__________________________________________________________________________

	Number	Date	Country
Parent	031655	Feb 1998
Parent	219262	Mar 1994

Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Parent Case Info

US Referenced Citations (1)

Foreign Referenced Citations (1)

Non-Patent Literature Citations (4)

Divisions (2)

Entry
Snyder et al. Arch. Virol. (1992) vol. 127 : 89-101.
Journal of General Virology, vol. 70, pp. 1473-1481, 1989, K.J. Fahey, et al., "A Conformation Immunogen on VP-2 of Infectious Bursal Disease Virus That Induces Virus-Neutralizing Antibodies That Passively Protect Chickens".
Archives of Virology, vol. 120, pp. 193-205, 1991, C.D. Bayless, et al, "A Recombinant Fowlpox Virus That Expresses the VP2 Antigen of Infectious Desease Virus Induces Protection Against Mortality Caused by the Virus".
Journal of General Virology, vol. 74, pp. 1201-1206, 1993, V.N. Vakharia, et al., "Infectious Bursal Disease Virus Structural Proteins Expressed in a Baculovirus Recombinant Confer Protection in Chickens".